^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Pegasys (pegylated interferon α -2a)

    i
    Other names: PEG IFN-alpha-2a, R442, R964, RG44, RG964, RO 253036, RO 25-8310, RO 258310, R 442, R 964, RG 44, RG 964, RO253036, RO258310, RO25-8310, R-442, R-964, RG-44, RG-964, RO-253036, RO-258310, RO-25-8310
    Company:
    Ascletis, Pharma& Schweiz, Roche
    Drug class:
    IFNα stimulant
    Related drugs:
    2ms
    PETALs: Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (clinicaltrials.gov)
    P3, N=200, Completed, Hospices Civils de Lyon | Unknown status --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Tasigna (nilotinib) • Pegasys (pegylated interferon α -2a)
    8ms
    A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C (clinicaltrials.gov)
    P1/2, N=30, Completed, HanAll BioPharma Co., Ltd. | Phase classification: P1b/2a --> P1/2
    Phase classification
    |
    Pegasys (pegylated interferon α -2a)
    10ms
    MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov)
    P1/2, N=316, Recruiting, Hoffmann-La Roche | N=510 --> 316
    Enrollment change
    |
    ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    10ms
    A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (clinicaltrials.gov)
    P1, N=267, Terminated, Bristol-Myers Squibb | N=132 --> 267 | Trial completion date: Mar 2025 --> Oct 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Oct 2024; Business objectives have changed
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Pegasys (pegylated interferon α -2a)
    10ms
    MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov)
    P1/2, N=510, Recruiting, Hoffmann-La Roche | Trial primary completion date: Apr 2026 --> Nov 2027
    Trial primary completion date
    |
    ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    11ms
    MORPHEUS BC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer (clinicaltrials.gov)
    P1/2, N=510, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2026 --> Nov 2027
    Trial completion date
    |
    ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • everolimus • Verzenio (abemaciclib) • Kisqali (ribociclib) • ipatasertib (RG7440) • Itovebi (inavolisib) • giredestrant (RG6171) • Pegasys (pegylated interferon α -2a) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • samuraciclib (CT7001)
    1year
    A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (clinicaltrials.gov)
    P1, N=132, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pegasys (pegylated interferon α -2a)
    over1year
    Piranga: A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B (clinicaltrials.gov)
    P2, N=281, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Jul 2024 | Trial primary completion date: Oct 2024 --> Jul 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy
    |
    Pegasys (pegylated interferon α -2a)
    over1year
    A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients (clinicaltrials.gov)
    P2, N=8, Completed, Shanghai HEP Pharmaceutical Co., Ltd. | Recruiting --> Completed | N=30 --> 8
    Trial completion • Enrollment change
    |
    Pegasys (pegylated interferon α -2a)
    over1year
    Piranga: A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B (clinicaltrials.gov)
    P2, N=280, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jan 2025 --> Jul 2025
    Trial completion date • Combination therapy
    |
    Pegasys (pegylated interferon α -2a)
    over1year
    A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants (clinicaltrials.gov)
    P1, N=132, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Pegasys (pegylated interferon α -2a)
    almost2years
    ACTIVATE: Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy (clinicaltrials.gov)
    P1/2, N=17, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed | N=34 --> 17
    Trial completion • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Farydak (panobinostat) • Pegasys (pegylated interferon α -2a)